We present a case of a 67-year-old Caucasian male, with history of hypertension, obesity, and previous hepatitis B infection. He was diagnosed with chronic lymphocytic B leukemia in 2011, treated with rituximab, cyclophosphamide, and fludarabine. His disease progressed in 2014 and was treated with 6 cycles of R-CHOP. Then, in 2015 a hematopoietic stem cell transplant (HSCT) from a related donor (fludarabin/bussulfan conditioning regimen) was performed. Cyclosporine A and mycophenolate mofetil were used for graft-versus-host disease (GVHD) prophylaxis and lamivudine for hepatitis B reactivation prophylaxis.
No takes yet. Share an insight, caveat, or question.
Ferreira et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: